Program overview
Context
Indication: Metastatic Breast Cancer
Mechanism: Unknown
Modality: Unknown
Sponsor: US Oncology Research
Low Signal
Pegylated liposomal doxorubicin
Pegylated liposomal doxorubicin is flagged as low signal because public records show limited public risk signal. This is a public-data monitoring signal, not a conclusion about clinical failure, regulatory noncompliance, or sponsor intent.
Scores
Risk-signal summary
Registry: 0/5
Timeline: 1/5
Recruitment burden: 1/5
Results availability: 0/5
Program risk: 1/5
Evidence
Public links
https://clinicaltrials.gov/study/NCT00303108
Linked trials
Trial-level signal details
| Trial | Status | Timeline | Results | Burden |
|---|---|---|---|---|
| NCT00303108 | Low Signal (COMPLETED) | stale_update_signal | Low Signal | strict_eligibility_signal |